

# ADRC Participant Access Request

## Access Request Goal

Goal - Preliminary inquiry for further discussion

## Principal Investigator

---

Name      Hongwei Qin

---

Title      Professor

---

Institution    UAB

---

Email      [hqin@uab.edu](mailto:hqin@uab.edu) (<mailto:hqin@uab.edu>)

---

Phone      (205) 934-2573

## Co-PI

---

Name      Xiaosi Han

---

Title      Associate Professor

---

Institution    UAB

---

Email      [xhan@uabmc.edu](mailto:xhan@uabmc.edu) (<mailto:xhan@uabmc.edu>)

---

Phone      (205) 934-1813

# Study and Theme Details

## Hypothesis

Our central hypothesis is that expression levels of VEGF impact vascular health in the brain and that of the HIF-VEGF signaling axis activation is protective against neurocognitive decline in ADRD.

## Specific Aims

Aim 1: Assess the mechanism of anti-VEGF therapy in the development of neurocognitive decline in mouse models.

Determine how the PHD-specific inhibitor, Roxadustat/FG-4592, regulates neurocognition using the HIF-VEGF pathway.

This study is not related to Deep South disparities

# Funding and IRB Details

Funding source - Not yet funded

IRB Contact - Not yet discussed project with IRB

# Subject Sample Size and Profile

## Sample size by cognitive ability

Normal Controls	10
Preclinical AD	10
MCI	10
Mild Dementia	10
Moderate to Severe	10
<b>Total N</b>	<b>50</b>

## Additional inclusion/exclusion details

For the first experiment, we would like to check the gene expression of HIF-1a, VEGFa, EPO, HO-1, ADM, and Glut-1 in the bio-samples at different AD disease stages.

## Racial minorities and other stratification

This study does NOT test hypothesis on racial disparities

# Requested Resources

## Existing data

Demographics	If available
Medical History	If available
Social Determinants	If available
Clinical Exam	If available
Cognitive Testing	If available
MRI Values	If available
Amyloid PET Values	If available
Tau PET Values	If available
Raw MRI/PET Image Files	If available
CSF	If available
Blood Test	If available
AD Blood Biomarkers	If available
Genetics	If available

## Human subject involvement

### Study procedures

If you have the RNA extraction, it will be great. If we could have the samples, which will work for us too.

### Study duration

2 months

No compensation listed in survey

# Banked biospecimen

## Blood

---

Plasma (100 ul)

---

Serum (100 ul)

---

RNA

## Other fluid

---

CSF (100 ul)

## Cells

---

PBMC

## Brain tissue

---

Fixed

---

Region (Cortex and hippocampus)

## Statistical support

Would like to discuss statistics with the ADRC